ArticleMedicine2026
Nasal nitric oxide in post-acute COVID-19 cough: A comparison with chronic cough and the role of current allergic rhinitis.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Post-acute COVID-19 cough (PACC) is a persistent or recurrent cough lasting >3 weeks after SARS-CoV-2 infection without other causes. This study examined nasal nitric oxide (nNO) in PACC patients to evaluate diagnostic and treatment potential. In this retrospective study, we enrolled 156 PACC patients after December 2022 and 161 chronic cough patients before December 2022. Compared to chronic cough patients, PACC patients had higher rates of current allergic rhinitis (60.9% vs 37.3%; P < .001), higher nNO levels (536 ± 192 ppb vs 483 ± 189 ppb; P = .014), and a greater proportion of elevated nNO (57.1% vs 42.9%; P = .012). Initial binary logistic regression indicated that both PACC (odds ratio [OR] = 1.771, 95% confidence interval [CI]: 1.135-2.764; P = .012) and current allergic rhinitis were associated with elevated nNO. However, multivariate logistic regression showed that only current allergic rhinitis remained an independent risk factor for elevated nNO (OR = 5.168, 95% CI: 3.121-8.558; P < .001), not PACC. Consistently, when comparing PACC patients without allergic rhinitis to chronic cough patients without it, no significant differences were found in nNO levels (436 ± 150 ppb vs 428 ± 179 ppb; P = .790) or elevated nNO rates (29.6% vs 29.3%; P = .971). The increased nNO observed in PACC patients compared to those with chronic cough is primarily driven by a higher concomitant prevalence of current allergic rhinitis in the PACC group, rather than by PACC itself.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.